Michael Tremblay, president and CEO of Astellas Pharma Canada, Inc., draws upon his four decades of experience within the Canadian pharmaceutical industry to discuss his thoughts on the need for Canada to move away from a ‘silo-ed’ approach to healthcare spending, the value that Astellas has been bringing to patients in Canada through its innovative products, and the significance of what he calls ‘the cocktail moment’.
Michael, as a veteran of the Canadian pharmaceutical industry with over 40 years of experience, how would you characterize this current period of regulatory and pricing changes and agreements?
"Market access timelines are extending, not just in terms of obtaining market approval but also all of the hurdles that occur post-approval."
